Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 13Melanoma 7Neoplasms 3Sarcoma, Kaposi 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Leukemia 2Kidney Neoplasms 2Hematologic Neoplasms 2HIV Infections 2Brain Neoplasms 2Acquired Immunodeficiency Syndrome 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Osteosarcoma 1Myeloproliferative Disorders 1Mycosis Fungoides 1Margins of Excision 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Hairy Cell 1Hodgkin Disease 1

Interventions

Cyclophosphamide 17Etoposide 10fludarabine 9Whole-Body Irradiation 9Brentuximab Vedotin 9Melphalan 8fludarabine phosphate 7Vincristine 7Mycophenolic Acid 7Gemcitabine 7Doxorubicin 7Prednisone 6Granulocyte Colony-Stimulating Factor 6Busulfan 6Vorinostat 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Filgrastim 5Cytarabine 5Bortezomib 5romidepsin 4pembrolizumab 4duvelisib 4Tacrolimus 4Stem Cell Transplantation 4Carmustine 4etoposide phosphate 3Sirolimus 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell × Interferon alpha-2 × Clear all
NCT00038376 2018-10-29

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
56 enrolled
LymphoidOther hematologic neoplasm

Mycosis Fungoides, Lymphoma, T-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡